Metabolic · Dosing reference

Adipotide dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: Not located in the sources reviewed; no pharmacokinetic half-life for any species was reported in the sources used for this entry.
Evidence grade: Grade C · Preclinical research
Vial sizes on the market: Not recorded
Other forms seen: —

What Adipotide is

Adipotide is a synthetic peptidomimetic designed to deliver a pro-apoptotic sequence to blood vessels of white fat; the primate study that defined it reported reversible renal proximal tubule changes at the doses judged optimal, and its single registered human trial was terminated after 4 participants with no results posted.

Adipotide is a cyclic CKGGRAKDC homing motif linked by Gly-Gly to D(KLAKLAK)2 ^2. The homing motif was identified by in vivo phage display in mice and reported to associate with prohibitin, which the authors established as a marker of white adipose tissue vasculature and described as also expressed in blood vessels of human white fat ^1. Proposed sequence of events Targeting: the CKGGRAKDC portion directs the… How it works →

Key evidence

Barnhart et al., Sci Transl Med · 2011 · Animals (obese rhesus macaques, baboons, cynomolgus macaques)
Reduced body weight, total body fat and insulinogenic index in obese rhesus monkeys; the primary side effect was renal proximal tubule injury with glucosuria, proteinuria and creatinine rises, described as predictable and reversible at optimal amounts. ²
Kolonin et al., Nat Med · 2004 · Animals (obese mice); human tissue for prohibitin expression
Identified the CKGGRAKDC motif binding prohibitin on white fat vasculature; the targeted pro-apoptotic peptide ablated white fat and reversed obesity in mice, with the authors reporting no detectable adverse effects. ¹
Kim et al., Diabetes · 2012 · Animals (obese high-fat-diet mice)
Glucose tolerance improved within days, independently of food intake and body-weight change, with lower serum insulin and triglycerides. ³

All studies on the research page

What the human evidence shows

No approved or established human dose

Human studies of Adipotide are listed below by design, population and duration. None was designed or powered to establish an amount, and Amiravo does not reproduce their amounts for a compound approved nowhere.

Single-arm, open-label, first-in-human phase 1 dose-escalation trial (NCT01262664), terminated per the principal investigator's request with no posted results; Men with metastatic castrate-resistant prostate cancer and obesity, no standard therapy options remaining; 4 participants; duration Study ran from May 2012 to January 2019; a single treatment cycle was planned per participant. ⁵

How long did human studies run?

No human study durations are recorded for Adipotide.

Cycle-length evidence for Adipotide

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

General research-context handling only: cysteine-containing peptides are sensitive to oxidation, and lyophilized material is generally kept dry and protected from light and moisture. Defer to supplier documentation for the specific lot. No temperatures, concentrations or preparation steps are given here.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved anywhere in the sources reviewed; no Drugs@FDA application record was returned for adipotide ^7. The defining primate study reported that monkeys at the doses the authors judged optimal showed predictable and reversible changes in renal proximal tubule function ^2. The only registered human study, phase 1 trial NCT01262664 at MD Anderson in men with metastatic castrate-resistant prostate cancer and obesity, began in 2012, enrolled 4 participants and was terminated per the principal investigator's request, with no results posted ^5.
United States (FDA): Not approved. An openFDA Drugs@FDA query for adipotide returned no application record on 24 October 2026 ^7. The only registered human study, phase 1 trial NCT01262664, was terminated in 2019 with no results posted ^5.
Sport (WADA): Not named individually in the sources reviewed; S0 covers substances without governmental approval for human therapeutic use, prohibited at all times ^8.

Status varies by country and changes over time. How we describe regulatory status.

Adipotide compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Adipotide	Not approved — research use only	C	None established	Not located in the sources reviewed; no
Vesugen	Not approved — research use only	C	None established	—
Tesofensine	Investigational	B	Trial doses	About 234 hours (M1 metabolite about 374
Mazdutide	Approved outside the US	A	Trial doses	150.9 to 403.5 hours (phase 1b in overwe
Cagrilintide	Investigational	A	Trial doses	159 to 195 hours (phase 1b, co-administe
SLU-PP-332	Not approved — research use only	C	None established	Unknown in humans

Frequently asked questions

What doses of Adipotide have been studied in humans?

None that establish an amount. Adipotide is not approved anywhere and the human studies that exist are small and were not designed to find a dose. Amiravo does not publish community or vendor figures.

Is there an established Adipotide cycle length?

No. We found no human studies that report treatment duration for Adipotide.

How much bacteriostatic water should be added to a Adipotide vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

What is the half-life of Adipotide?

Not located in the sources reviewed; no pharmacokinetic half-life for any species was reported in the sources used for this entry.

Is Adipotide FDA-approved?

Not approved — research use only. Not approved anywhere in the sources reviewed; no Drugs@FDA application record was returned for adipotide ^7. The defining primate study reported that monkeys at the doses the authors judged optimal showed predictable and reversible changes in renal proximal tubule function ^2. The only registered human study, phase 1 trial NCT01262664 at MD Anderson in men with metastatic castrate-resistant prostate cancer and obesity, began in 2012, enrolled 4 participants and was terminated per the principal investigator's request, with no results posted ^5.

References

Reversal of obesity by targeted ablation of adipose tissue Nat Med. 2004
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys Sci Transl Med. 2011
Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium Diabetes. 2012
Comment on "A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys" Sci Transl Med. 2012
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity (NCT01262664) ClinicalTrials.gov. 2019
Adipotide (CID 163360068) PubChem. 2026
Drugs@FDA application data queried through openFDA for adipotide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026

Last reviewed October 24, 2026 by the Amiravo editorial team. Editorial policy · Report an error